#Novartis #SMA #spinalmuscularatrophy #genetherapy #Itvisma #SMAgenetherapy #onasemnogeneabeparvovec #patientpopulation #EC #SMApatients #Zolgensma #geneticneuromusculardisease #STEERstudy #STRENGTHtrial #SMAcommunity #patientadvocacy #SMAEurope #reimbursement #genetherapies
zurl.co/NupjG
zurl.co/NupjG
Novartis' new SMA gene therapy cleared in EU
Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.
pharmaphorum.com
July 6, 2026 at 10:03 AM